A phase 1 dose-escalation study of XmAb® 2513 in patients with relapsed or refractory Hodgkin lymphoma. Article uri icon

Overview

publication date

  • October 1, 2014

Research

keywords

  • Antineoplastic Agents
  • Hodgkin Disease

Identity

Scopus Document Identifier

  • 84924083411

Digital Object Identifier (DOI)

  • 10.1111/bjh.13152

PubMed ID

  • 25271537

Additional Document Info

volume

  • 168

issue

  • 6